Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Short term Debt (2022 - 2025)

Cue Biopharma (CUE) has disclosed Short term Debt for 4 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • Quarterly Short term Debt fell 63.21% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Sep 2025, down 63.21% year-over-year, with the annual reading at $4.3 million for FY2024, 9.34% up from the prior year.
  • Short term Debt hit $1.5 million in Q3 2025 for Cue Biopharma, down from $2.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.3 million in Q4 2024 to a low of $1.0 million in Q3 2022.
  • Historically, Short term Debt has averaged $3.2 million across 4 years, with a median of $4.0 million in 2023.
  • Biggest five-year swings in Short term Debt: soared 300.0% in 2023 and later crashed 63.21% in 2025.
  • Year by year, Short term Debt stood at $2.0 million in 2022, then soared by 101.88% to $4.0 million in 2023, then grew by 9.34% to $4.3 million in 2024, then tumbled by 66.35% to $1.5 million in 2025.
  • Business Quant data shows Short term Debt for CUE at $1.5 million in Q3 2025, $2.4 million in Q2 2025, and $3.4 million in Q1 2025.